Skip to content

Acetyl-L-carnitine and mental fatigue: grade C

Limited evidence. Direction: No effect.

Evidence maturity: EmergingSingle research groupSubjective outcome only

Why this grade

Rubric condition met: Small RCTs only in clinical/older populations (adults over 70 with fatigue; hepatic encephalopathy) extrapolated to healthy adults

Controlled trials in adults over 70 with fatigue (96 participants; the abstract does not describe the comparison group) and in hepatic encephalopathy (121 patients) reported lower mental-fatigue scores, but every fatigue trial found shares the same research team (Malaguarnera M is an author on each). The only fatigue data in the 2019 Cochrane review of that team's hepatic encephalopathy trials come from the same 121-patient trial [11], re-analyzed; the review rated it very low quality and judged the effects uncertain. No trials in healthy adults were found. Both positive trials come from one team at high risk of bias, and the outcomes are self-reported, so direction is none (limited, mixed), not benefit.

How sure are we?

Evidence maturity: Emerging Every supporting fatigue trial comes from one research group, so the replication rule holds it at Emerging.

Tested as: Acetyl-L-carnitine

Who paid for the studies
Not stated (treated as not independent)
Risk of bias
High. Cochrane rated the group's trials high risk of bias, underpowered and very low quality.
Trial registry check
Not checked yet
Outcome measured
A test score, rating scale or performance measure
Who was studied
Clinical populations only
Doses used in studies
1.5 g a day or more
Rules applied
B1: risk of bias (logged, no further change): Over half the supporting studies are high risk of bias; step stops at C; B2: one funder or group (logged, no further change): Every supporting trial shares one research group
  • Could rise: Would move to C benefit with an independent, preregistered RCT of at least 100 adults positive on a fatigue primary outcome; to B with two such trials.
  • Could fall: Stays at C none unless two adequately sized independent RCTs are null, which would support N.

Science is provisional. This grade reflects the evidence we found as of . Next review: .

Maturity sits beside each grade. The grade says what the evidence shows; maturity says how much of it there is and how well it is confirmed.

Established
many trials from several independent teams, including at least one registered in advance
Emerging
two or more trials, or one large registered trial, not yet independently confirmed
Early signal
one trial, small pilots, or results only on secondary outcomes
Mechanistic only
lab, animal or biomarker data, or uncontrolled reports; no controlled human results
Traditional use only
a traditional-use monograph and nothing else

How we grade evidence

Studies this grade rests on

EffectMixedNo effectSize shows participants (n)20052010201520202025Meta-analysisRCTMart 2019, 2019: meta-analysis, n = 398, result not recordedMalaguarnera 2011, 2011: RCT, n = 121, result not recordedMalaguarnera 2008, 2008: RCT, n = 96, result not recordedMalaguarnera 2022, 2022: RCT, n = 92, result not recorded
each study this grade rests on, by publication year and design. Solid: effect versus the comparator; half-filled: mixed; hollow: no effect; dashed: result not recorded yet. Larger marks had more participants.
Show the numbers
StudyYearDesignParticipantsResult
Malaguarnera 20082008RCT96result not recorded
Malaguarnera 20112011RCT121result not recorded
Mart 20192019meta-analysis398result not recorded
Malaguarnera 20222022RCT92result not recorded

Acetyl-L-carnitine for patients with hepatic encephalopathy.

Martí-Carvajal AJ, Gluud C, Arevalo-Rodriguez I. Acetyl-L-carnitine for patients with hepatic encephalopathy Cochrane Database Syst Rev, 2019. PMID 30610762

Result not recorded
Design
Cochrane systematic review and meta-analysis of 5 RCTs
Sample
n = 398
Population
Adults with cirrhosis and hepatic encephalopathy (clinical population)
Funding
not stated

Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

Malaguarnera M, Vacante M, Giordano M. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study Am J Clin Nutr, 2011. PMID 21310833

Result not recorded
Design
Randomized double-blind placebo-controlled trial, 90 days
Sample
n = 121
Population
Adults with cirrhosis and overt hepatic encephalopathy (clinical population)
Funding
not stated

Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial.

Malaguarnera G, Catania VE, Bertino G. Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A Randomized Interventional Clinical Trial Curr Pharm Des, 2022. PMID 36043711

Result not recorded
Design
Randomized double-blind placebo-controlled trial (abstract also calls it 'observational')
Sample
n = 92
Population
Prefrail older adults (older population)
Funding
not stated

Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue.

Malaguarnera M, Gargante MP, Cristaldi E. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue Arch Gerontol Geriatr, 2008. PMID 17658628

Result not recorded
Design
Randomized placebo-controlled trial
Sample
n = 96
Population
Adults over 70 with chronic fatigue complaints meeting fatigue-syndrome criteria (clinical/older population)
Funding
not stated

Search and history

Search (): (acetylcarnitine[ti] OR acetyl-L-carnitine[ti] OR "acetyl L carnitine"[ti]) AND (fatigue[tiab]) AND (randomized controlled trial[pt] OR meta-analysis[pt])

  • Graded C (awaiting approval)
  • C to C (awaiting approval)
  • C to C (awaiting approval) (maturity: emerging): Maturity, bias summary and re-check date added
  • C to C (approved) (maturity: emerging): Editor sign-off November 16, 2026: grade matches the editor-approved final page